Focus: NMD Pharma is a small-molecule drug discovery company focused on neurology and rare diseases, operating as a Series A biotech with 51-200 employees based in Aarhus, Denmark.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow NMD Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
ANDA pre-launch formulation; minimal current revenue.
Help build intelligence for NMD Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NMD Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Mature generic combination; post-LOE with no disclosed revenue.
ANDA pre-launch variant; minimal commercial contribution.
Serotonin and histamine antagonist; pre-launch ANDA with no disclosed revenue.
ANDA post-LOE formulation; mature generic with no disclosed revenue.
6 discontinued, 4 duplicate formulations not shown
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ - GlobeNewswire
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ GlobeNewswire
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ openPR.com
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial.
Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.
Showing 5 of 6 publications